Ian is an independent consultant with expertise in regulatory and scientific aspects of nicotine and tobacco products. His current consulting work focusses on advising manufacturers on regulatory requirements for e-cigarettes as both consumer goods and medicinally-licensed products, in the US, UK and Europe. His consulting work also provides human studies services to companies, including clinical and behavioural studies. Prior to independent consulting, Ian worked for JUUL Labs as Senior Director of Clinical and Regulatory Affairs EMEA, and previously he was Director of Tobacco Research at Celerion, a provider of clinical research capabilities and regulatory expertise to the tobacco and e-cigarette industries. Prior to that, Ian was Principal Scientist and Head of Clinical Research at British American Tobacco’s central research and development centre in Southampton, U.K. He specializes in the biological and psychological effects of nicotine, , clinical and behavioural studies to assess the individual and population impact of electronic cigarettes and tobacco heating devices, and the scientific basis for regulation. Prior to working in the industry, Ian pursued an academic career as a Lecturer in Physiology at the University of Manchester and an Assistant Professor in Biology at McMaster University in Hamilton, Canada. Ian is a highly-cited scientific researcher and writer, contributing to more than 50 peer-reviewed papers and book chapters which have generated over 2,900 citations.
Ian Fearon
